California-based diagnostics firm Cepheid intends to use the US Food and Drug Administration's Emergency Use Authorisation pathway for regulatory approval and make the test available globally. - ST
BEIJING/CALIFORNIA (Caixin Global): As fears mount that an existing test to identify the coronavirus is failing to catch many of those infected, California-based diagnostics firm Cepheid said on Monday (Feb 10) that it is developing an automated molecular test that is expected to deliver results in about 30 minutes.
Once the product is finalised, Cepheid intends to use the US Food and Drug Administration's Emergency Use Authorisation pathway for regulatory approval and make the test available globally. The company did not say when the new test would be available.
Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.
